AVITA Medical Inc RCEL Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$16.59 up $0.91, 5.80% at close Nov 6
Last close · Previous close $15.68
- Market cap
- $510.59MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.43Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$16.59up $0.91, 5.80%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$15.68Nov 5
- Volume1.14MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume493.81KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $3.22 to $18.07; now $16.59
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
RCEL beat the S&P 500 in 4 of 6 periods.
| Period | RCEL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RCEL: up 27.7% S&P 500: down 5.6% | RCEL beat the S&P 500 by 33.3 percentage points Beat |
| 3M | RCEL: up 249.3% S&P 500: down 4.1% | RCEL beat the S&P 500 by 253.4 percentage points Beat |
| YTD | RCEL: up 380.9% S&P 500: up 8.7% | RCEL beat the S&P 500 by 372.2 percentage points Beat |
| 1Y | RCEL: up 387.9% S&P 500: up 10.9% | RCEL beat the S&P 500 by 377.0 percentage points Beat |
| Long term | ||
| 3Y | RCEL: up 59.1% S&P 500: up 75.0% +16.7% vs +20.5% a year | RCEL trailed the S&P 500 by 15.9 percentage points Trailed |
| 5Y | RCEL: down 15.6% S&P 500: up 67.8% −3.3% vs +10.9% a year | RCEL trailed the S&P 500 by 83.4 percentage points Trailed |
$10,000 invested in RCEL 5 years ago (Nov 5, 2021) would be worth about $8,438 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
RCEL beat the S&P 500 in 4 of 6 periods.
| Period | RCEL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RCEL: up 27.7% S&P 500: down 5.6% | RCEL beat the S&P 500 by 33.3 percentage points Beat |
| 3M | RCEL: up 249.3% S&P 500: down 4.3% | RCEL beat the S&P 500 by 253.6 percentage points Beat |
| YTD | RCEL: up 380.9% S&P 500: up 7.8% | RCEL beat the S&P 500 by 373.1 percentage points Beat |
| 1Y | RCEL: up 387.9% S&P 500: up 9.7% | RCEL beat the S&P 500 by 378.2 percentage points Beat |
| Long term | ||
| 3Y | RCEL: up 59.1% S&P 500: up 68.8% +16.7% vs +19.1% a year | RCEL trailed the S&P 500 by 9.7 percentage points Trailed |
| 5Y | RCEL: down 15.6% S&P 500: up 56.9% −3.3% vs +9.4% a year | RCEL trailed the S&P 500 by 72.5 percentage points Trailed |
$10,000 invested in RCEL 5 years ago (Nov 5, 2021) would be worth about $8,438 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$55.20
Closing high on . Now 69.9% below that record.
Split-adjusted daily closes since Oct 1, 2019.
Stock splits
1
1-for-5 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$1.43 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 6.8×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - −4.94%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $547.93MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own RCEL DCF in Excel. Value AVITA Medical with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $75.63Mup 1.0%
- Net income
- −$43.08M
- Diluted EPS
- −$1.43
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $19.55M | −$16.21M | −$0.62 |
| Q4 FY24 (Dec 31, 2024) | $18.41M | −$11.59M | −$0.44 |
| Q1 FY25 (Mar 31, 2025) | $18.51M | −$13.86M | −$0.53 |
| Q2 FY25 (Jun 30, 2025) | $18.42M | −$9.92M | −$0.38 |
| Q3 FY25 (Sep 30, 2025) | $17.06M | −$13.19M | −$0.46 |
| Q4 FY25 (Dec 31, 2025) | $17.62M | −$11.62M | −$0.37 |
| Q1 FY26 (Mar 31, 2026) | $19.25M | −$10.61M | −$0.35 |
| Q2 FY26 (Jun 30, 2026) | $21.70M | −$7.66M | −$0.25 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $34.62M | −$25.14M | −$1.01 |
| FY22 (Dec 31, 2022) | $37.64M | −$26.67M | −$1.07 |
| FY23 (Dec 31, 2023) | $51.57M | −$35.38M | −$1.40 |
| FY24 (Dec 31, 2024) | $64.25M | −$61.85M | −$2.39 |
| FY25 (Dec 31, 2025) | $71.61M | −$48.59M | −$1.74 |
Margins
- Gross 81.6%
- Operating −46.6%
- Net −57.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$25.25MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$24.23MLast 12 months
- Capital spending$1.02MLast 12 months
- −33.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $15.51MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $11.14MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$48.48MAs of Jun 30, 2026
- Net debt$37.35MAs of Jun 30, 2026
- 0.41As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −78.5%Last 12 months
Over the last 12 months, AVITA Medical’s net loss was 78.5% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About AVITA Medical Inc
AVITA Medical, Inc. is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical Inc. patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment. AVITA Medicals’ first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL® System is approved for acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. The RECELL® System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL® System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL® System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
RCEL news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
RCEL stock FAQ
What is RCEL stock’s price today?
AVITA Medical (RCEL) traded at $16.59 at the close on , up $0.91 (5.80%) from the previous close of $15.68. Over the past 52 weeks it has traded between $3.22 and $18.07.
If you invested $1,000 in RCEL 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in RCEL on would be worth about $844 at the close on , a total return of −15.6%. The same $1,000 would be worth $4,879 if invested one year ago. Past performance doesn’t predict future returns.
What is AVITA Medical’s market cap?
AVITA Medical’s market capitalization is about $510.6 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $16.59 (how market cap works). AVITA Medical reported 30.78M shares outstanding at the end of its latest quarter ().
What is RCEL’s P/E ratio?
RCEL’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.43).
How much revenue does AVITA Medical make?
AVITA Medical reported $75.6 million of revenue over the four quarters to , up 1.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $21.7 million, up 17.8% from a year earlier.
Is AVITA Medical profitable?
Not over the four quarters to . AVITA Medical reported a net loss of $43.1 million across those four quarters on $75.6 million of revenue.
What are RCEL’s earnings per share?
RCEL’s diluted earnings per share were −$1.43 over the four quarters to , compared with −$1.97 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.25 per share, against −$0.38 a year earlier (how EPS works).
Does RCEL pay a dividend?
AVITA Medical hasn’t paid a dividend in the last twelve months.
What is RCEL’s 52-week high and low?
Over the past 52 weeks RCEL has traded as low as $3.22 and as high as $18.07. At $16.59 at the close on , it is 8.2% below that high and 415.2% above the low.
What is RCEL’s all-time high?
RCEL’s highest closing price was $55.20 on , adjusted for stock splits. At $16.59 at the close on , it is 69.9% below that record.
Has RCEL stock ever split?
Yes, once: 1-for-5 on .
How has RCEL stock performed?
Including dividends and measured to the close on , RCEL has returned +380.9% so far this year and +387.9% over the past year, and −15.6% over five years (−3.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is AVITA Medical in?
AVITA Medical is in the Healthcare sector and the Medical Devices industry, and is headquartered in California, USA.
What exchange does RCEL trade on?
AVITA Medical trades on the Nasdaq under the ticker symbol RCEL. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.